Major Estimate Revision • Jun 14
Consensus revenue estimates increase by 35% The consensus outlook for revenues in fiscal year 2026 has improved. 2026 revenue forecast increased from US$4.50m to US$6.08m. Forecast losses expected to reduce from -US$0.059 to -US$0.05 per share. Medical Equipment industry in Canada expected to see average net income growth of 13% next year. Consensus price target down from CA$1.82 to CA$1.73. Share price was steady at CA$0.29 over the past week. Announcement • Jun 10
Perimeter Medical Imaging AI Announces Selection for INOVAIT Pilot Fund to Advance Next-Generation AI Capabilities for Claire Perimeter Medical Imaging AI, Inc. announced it has been selected to receive a contribution from the INOVAIT Pilot Fund to advance next-generation AI capabilities for its flagship product Claire, which received U.S. Food and Drug Administration approval earlier this year as the first AI-enabled imaging device for use during breast cancer surgery. Claire addresses that problem, combining wide-field OCT imaging with proprietary AI to help surgeons see microscopic cancer in the operating room, guiding them to areas that warrant a closer look, particularly in the critical margin zone where cancer is most likely to be missed. Claire works alongside other intraoperative margin assessment techniques, giving surgeons additional intelligence that combines real-time imaging with AI detection support before post-operative pathology evaluation. The project will focus on building more robust and scalable AI to support continued improvement of Perimeter's OCT+AI platform. The Company expects to receive up to nearly $148,000 in INOVAIT contributions. An additional $100,000 Mitacs Business Strategy Internship award will support graduate student participation through the university collaboration. The project is conducted in partnership with Dr. Ervin Sejdic, Professor in the Edward S. Rogers Sr. Department of Electrical and Computer Engineering at the University of Toronto. The work supported by this contribution will target four specific areas: developing tools to reduce the burden of manual expert labeling required to train AI models; building a clearer understanding of how the AI performs across different tissue types and disease presentations; designing a two-tier AI architecture that combines fast initial screening with more detailed follow-up analysis; and optimizing the system for efficient performance on the hardware used in operating room environments. The future deployment of these capabilities will proceed in accordance with standard FDA review processes for class III devices. INOVAIT is a pan-Canadian network funded by the Government of Canada and hosted at the Sunnybrook Research Institute with the objective of building a truly integrated image-guided therapy and artificial intelligence (AI) ecosystem, fueling continuous innovation that revolutionizes healthcare globally. Funding for this project was provided in part by INOVAIT through the Government of Canada's Strategic Response Fund. The Claire OCT System is an adjunctive three-dimensional imaging tool which provides volumetric cross-sectional, real-time depth visualization, coupled with an artificial intelligence computer-aided detection algorithm which identifies and marks focal areas suspicious for breast cancer. It is used concurrently with physician interpretation of the images. The Claire OCT System is intended for use in conjunction with other standard methods for evaluation of the margins of excised lumpectomy tissue during surgical procedures in patients with a biopsy-confirmed diagnosis of breast cancer. The Claire OCT System should not be used to replace standard tissue histopathology assessment and should not be used for diagnosis. The device is not intended for use in any of the following individuals: under the age of 18, male, have metastatic cancer (Stage IV), have lobular carcinoma as their primary diagnosis, have had previous ipsilateral breast surgery for benign or malignant disease within two years (including implants and breast augmentation), patients with multi-centric disease (histologically diagnosed cancer in two different quadrants of the breast), unless resected in a single specimen, patients with bilateral disease (diagnosed cancer in both breasts), patients who are currently lactating, patients who are currently pregnant, or concurrent use in surgeries with cryo-assisted localization. Refer to prescriber labeling for full safety information. Announcement • Jun 09
Perimeter Medical Imaging AI, Inc. announced that it has received CAD 13.56115 million in funding from SC Master Holdings, LLC On June 8, 2026, Perimeter Medical Imaging AI, Inc. closed the transaction by closing its final tranche. The tranche consists of CAD 3,280,000 principal amount of Convertible Debentures. Each Debenture Unit will be comprised of one common share in the capital of the Company and one Common Share purchase warrant. Each Debenture Warrant shall entitle the holder to acquire one Common Share until April 27, 2031, at an exercise price of CAD 0.59 
